Building Your Treatment Plan: Steroids, Gene Therapies, and Exon Skipping

Navigating the treatment landscape for Duchenne Muscular Dystrophy (DMD) can be overwhelming. It is important to know that we are in a new era of care where several therapies are now FDA-approved and considered the “standard of care,” rather than experimental. Your child’s treatment plan will likely be built on three main pillars: protective steroids, precision “patching” drugs, and gene replacement therapy ^[1][2].

Pillar 1: Corticosteroids (The Foundation)

Corticosteroids are the baseline for DMD care. They work by reducing muscle inflammation and have been proven to help children stay walking longer, protect heart and lung function, and reduce the need for spine surgery ^[1][3].

• Prednisone and Deflazacort: These are the traditional options. Daily dosing is now preferred over “intermittent” (on-and-off) schedules because it provides better long-term muscle protection ^[4]. Side effects can include weight gain, “moon face,” and potential thinning of the bones ^[5].
• Vamorolone (Agamree): This is a newer, “dissociative” steroid. It was designed to provide the same muscle benefits as traditional steroids but with fewer side effects, such as less impact on bone health and growth ^[6][7].

Pillar 2: Exon Skipping (Precision Patching)

If your child’s genetic report shows a specific type of mutation (usually a deletion), they may be eligible for exon-skipping therapy. These drugs act like a molecular “patch” that allows the body to skip over a missing section of the gene to create a shorter but functional version of the dystrophin protein ^[8][9].

These treatments are given as a weekly intravenous (IV) infusion. Eligibility is strictly based on the genetic “address” of the mutation ^[10]:

• Eteplirsen (Exondys 51): Targets Exon 51.
• Golodirsen (Vyondys 53) and Viltolarsen (Viltepso): Target Exon 53.
• Casimersen (Amondys 45): Targets Exon 45.

Pillar 3: Gene Therapy (Blueprint Delivery)

Delandistrogene moxeparvovec (Elevidys) is an FDA-approved gene therapy ^[2]. Unlike weekly infusions, this is a one-time IV treatment designed to deliver a new, working version of the dystrophin gene (called “micro-dystrophin”) directly to the muscles ^[11].

Eligibility and Safety:

• Age and Mutation: It is approved for pediatric patients with a confirmed DMD mutation ^[2].
• The Exon 8/9 Warning: Patients with deletions in Exon 8 and/or Exon 9 are generally not eligible for this therapy, as they have a significantly higher risk of a serious immune reaction called immune-mediated myositis (severe muscle inflammation) ^[12].
• Antibody Testing: Before receiving gene therapy, your child must have a blood test to check for AAV antibodies. If their immune system has “seen” the virus used to deliver the gene before, the therapy may be blocked and ineffective ^[13].

Building the Plan

Your doctor will use your child’s genetic report as the master key. Because these are all FDA-approved treatments, they should be part of a standard conversation at any certified neuromuscular center. Your goal is to work with your “care team” to layer these treatments in a way that best supports your child’s strength and overall health ^[14].

Return to the Home Page.